



New Markers in the Early Diagnosis and Prognostic Evaluation of Ovarian Cancer

Guest Editor:

Dr. Francesco Raspagliesi

IRCCS Ist Nazl Tumori Milano,
Gynecol Oncol Unit, I-20133
Milan, Italy

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editor

Gynecological cancers represent one of the leading causes of cancer-related deaths in women. Compared to other types of cancer, gynecological cancers are uncommon, but their incidence is increasing, likely attributable to the aging of populations and increased prevalence of obesity in the developed world. The main types of gynecological cancer that affect a woman's reproductive organs are cervical, ovarian, uterine, vaginal, and vulvar tumors. The mainstay of treatment for gynecological cancer includes multimodal therapy with optimal surgery, chemotherapy, and radiotherapy. The introduction of effective screening methods and efforts to achieve early diagnoses will allow improving the outcomes of these patients. In recent years, the introduction of innovative diagnostic methods and innovative surgical, as well as medical, treatments have improved early detection and the outcomes for gynecological cancer patients. The objective of the current Special Issue in *Cancers* is to publish original research papers and reviews from authors who are interested in addressing these challenges and provide new insights and novel treatment strategies for patients with gynecological cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)